James Treace - Jul 13, 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor, as Attorney-in-fact for James T. Treace
Stock symbol
TMCI
Transactions as of
Jul 13, 2022
Transactions value $
-$255,006
Form type
4
Date filed
7/15/2022, 06:07 PM
Previous filing
Jun 21, 2022
Next filing
Jul 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$73.3K -4.54K -0.35% $16.13 1.28M Jul 13, 2022 Direct F1, F2
transaction TMCI Common Stock Sale -$44.9K -2.8K -0.22% $16.03 1.28M Jul 14, 2022 Direct F1, F3
transaction TMCI Common Stock Sale -$137K -8.46K -0.66% $16.18 1.27M Jul 15, 2022 Direct F1, F4
holding TMCI Common Stock 556K Jul 13, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.82 to $16.3475 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.67 to $16.47 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.